Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multiplexed Heptapeptides for Esophageal Neoplasia Detection
NCT03589443Phase 1Completed
- Sponsor
- University of Michigan
- Start
- May 2018
- Primary completion
- Feb 2019
- Modality
- Small Molecules, Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
Phase 1, open-label trial of QRH and KSP-910638G in Barrett's esophagus, sponsored by University of Michigan. Primary endpoint: Validation of peptide binding using SFE at 1 year. Started May 2018; status: completed.
02
Drugs
QRHKSP-910638G
03
Conditions
Barrett's esophagus
Beyond the preview
Go deeper on NCT03589443.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03589443.